Sarah Qayum, MD
Allergy & Immunology · Metairie, LANPI 1942654330
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,919 of the $10,761 with a category attached, or 82.9%. 25 manufacturers reported payments, led by Sanofi at 25.1% of the total. 2025 is the largest year on record at $5,658, more than ten times the $103 reported in 2021.
Across 359 payments — averaging $29.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$3K
- AstraZeneca$2K
- Regeneron Healthcare Solutions, Inc.$1K
- GSK$802
- CSL Behring$697
- Takeda Pharmaceuticals U.S.A., Inc.$599
- plus $3K from 19 others
What the payments were for
- Consulting fees$1,44613%
- Food & beverage$8,91983%
- Education$3964%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 35 | $2,700 |
| AstraZeneca | 52 | $1,743 |
| Regeneron Healthcare Solutions, Inc. | 53 | $1,317 |
| GSK | 46 | $802 |
| CSL Behring | 24 | $697 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $599 |
| Pfizer | 35 | $502 |
| Amgen | 16 | $401 |
| AbbVie | 13 | $306 |
| Aerin Medical Inc. | 3 | $294 |
| Novartis | 14 | $271 |
| Biocryst US Sales Co., LLC | 8 | $199 |
| Incyte Corporation | 5 | $186 |
| Grifols USA, LLC | 9 | $184 |
| Ionis Pharmaceuticals, Inc. | 5 | $172 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $87 |
| LEO Pharma Inc. | 4 | $74 |
| Genentech USA, Inc. | 2 | $64 |
| GC Biopharma USA, Inc. | 2 | $34 |
| Galderma Laboratories, L.p. | 2 | $30 |
| Paratek Pharmaceuticals, Inc. | 1 | $24 |
| Alk-abello, Inc | 1 | $24 |
| Azurity Pharmaceuticals, Inc. | 1 | $19 |
| Pharming Healthcare, Inc. | 1 | $17 |
| Phadia US Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEZSPIRE$848
- DUPIXENT$833
- FASENRA$238
- VIVAER STYLUS$220
- RHINAER STYLUS$220
- AIRSUPRA$113
How this compares
$10,761 in reported general payments places this provider in the 85th percentile of 62 allergy & immunology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TakhzyroLanadelumab-Flyo | 14 | $929,110 |
| IcatibantIcatibant Acetate | 13 | $201,658 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 30 | $181,311 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 25 | $122,776 |
| Dupixent PenDupilumab | 14 | $68,110 |
| Dupixent SyringeDupilumab | 18 | $66,989 |
| XolairOmalizumab | 14 | $38,931 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 54 | $35,109 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 12 | $34,431 |
| Epinephrine | 48 | $10,440 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $7,027 |
| Advair HfaFluticasone Propion/Salmeterol | 15 | $5,686 |
| Azelastine Hcl | 76 | $2,271 |
| Wixela InhubFluticasone Propion/Salmeterol | 11 | $1,399 |
| Fluticasone Propionate | 75 | $1,332 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Takhzyro, Gammagard Liquid | $599 | $1,110,42144 claims |
| CSL BehringHizentra | $697 | $122,77625 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $802 | $42,13665 claims |
| PfizerOctagam | $502 | $34,43112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 62 allergy & immunology providers in Louisiana.
Other allergy & immunology in Metairie
- David SchneiderMetairie$10K
- Jeffery FranklinMetairie$9K
- Sweta ShahMetairie$7K
- Alice HoytMetairie$7K
- Tammy HarveyMetairie$7K
- Alan SheenMetairie$4K
- David KaufmanShreveport$678K
- Reena MehtaNew Orleans$159K
- Kenneth ParisNew Orleans$150K
- Brice RolstonCovington$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.